EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of splenectomy in chronic myelogenous leukemia



Evaluation of splenectomy in chronic myelogenous leukemia



Surgery, Gynecology & Obstetrics 142(5): 689-692



Splenectomy was performed in 45 patients with chronic myelogenous leukemia; 23 were in the chronic phase and 22 in the acute phase. Indications for operation included inability to control the disease by chemotherapy or radiation therapy, severe thrombocytopenia, frequent need for blood transfusion and extensive splenomegaly causing discomfort. Median survival time for these patients was better than survival time of other reported groups of patients who did not have a splenectomy. According to our criteria, splenectomy was beneficial to 15 patients in the chronic phase as well as to eight in the acute phase of chronic myelogenous leukemia. Median survival time after splenectomy was higher in patients who had splenectomy within two years of the diagnosis as compared with those who had the operation after two years. Splenectomy did not prevent the future onset of fatal blastic crisis. Although significant abnormalities in coagulation studies were seen in 37 of the patients, intraoperative hemorrhage was not a major problem. Considering the poor general condition, inadequate healing and susceptibility to infection, the postoperative mortality and complication rates were comparable with those reported in series in which splenectomy was performed for other diseases. It seems that splenectomy benefits a selected group of patients with chronic myelogenous leukemia; however, a randomized series would furnish better data upon which to make decisions.

(PDF emailed within 1 workday: $29.90)

Accession: 005401873

Download citation: RISBibTeXText

PMID: 1063451



Related references

Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapy. Series Haematologica 8(4): 143-156, 1975

Stimulating capacity of leukemia cells from acute non-lymphocytic leukemia, chronic myelogenous leukemia, blastic crisis of chronic myelogenous leukemia, and chronic myelomonocytic leukemia in allogenic 'one way' mixed lymphocyte tumor cell reaction. Nihon Ketsueki Gakkai Zasshi 43(5): 796-804, 1980

Stimulating capacity of leukemia cells from acute nonlymphocytic leukemia chronic myelogenous leukemia blastic crisis of chronic myelogenous leukemia and chronic myelo monocytic leukemia in allogeneic 1 way mixed lymphocyte tumor cell reaction. Acta Haematologica Japonica 43(5): 796-804, 1980

Splenectomy in chronic myelogenous leukemia in Japan. Japanese Journal of Clinical Hematology 19(4): 400-408, 1978

Splenectomy in children with chronic myelogenous leukemia. Clinical Research 20(1): 99, 1972

Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. Journal of Immunology 187(4): 1653-1663, 2011

Early splenectomy in chronic myelogenous leukemia: surgical aspects. American Surgeon 47(5): 219-223, 1981

Splenectomy in chronic myelogenous leukemia results of a pilot study. Proceedings of the American Association for Cancer Research 15: 163, 1974

Chronic myelogenous leukemia: management of splenectomy in a high-risk population. Cancer 39(2): 653-658, 1977

Butadiene cancer exposure-response modeling: based on workers in the styrene-butadiene-rubber industry: total leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia. Regulatory Toxicology and Pharmacology 60(3): 332-341, 2011

A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. Chemico-Biological Interactions 241: 50-58, 2016

Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. Journal of Clinical Oncology 3(2): 192-200, 1985

Response of chronic myelogenous leukemia patients to COAP-splenectomy. A Southwest Oncology Group study. Cancer 54(9): 1977-1982, 1984